NCT02776163View on ClinicalTrials.gov

Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas

PHASE2CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions

Salivary Gland TumorsHead and Neck Cancer

Interventions

DRUG

Nedaplatin

nedaplatin 35mg/m\^2，D1-2，2 cycles

DRUG

Docetaxel

Docetaxel 70mg/m\^2，D1，2 cycles

RADIATION

Intensity-modulated radiotherapy

a total dose of 60-66Gy in 30-33 fractions over 6-7 weeks

Trial Locations (1)

200011

Shanghai ninth people's hospital, Shanghai

All Listed Sponsors

lead

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER

NCT02776163 - Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas | Biotech Hunter | Biotech Hunter